Clin Mol Hepatol.  2018 Sep;24(3):311-318. 10.3350/cmh.2017.0070.

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

  • 1Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
  • 2Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 3Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
  • 4Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
  • 5Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
  • 6Department of Internal Medicine, College of Medicine, Catholic University of Korea, Daejeon, Korea.
  • 7Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea.
  • 8Department of Internal Medicine, Konkuk University School of Medicine, Chungju, Korea.


Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27-96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.


Sofosbuvir; Ribavirin; Hepatitis C virus; Korea
Full Text Links
  • CMH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: